相关实验视频
Updated: Jul 1, 2025

07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
97
脂质体:一种新兴的策略,有效治疗类风湿性关节炎
Vani1, Priyanka Kriplani1, Ashwani Dhingra1
1Guru Gobind Singh College of Pharmacy, Yamuna Nagar 135001, Haryana, India.
Current rheumatology reviews
|March 5, 2024
概括
脂质体药物递送系统为治疗类风湿性关节炎提供了一个有希望的,生物相容的方法. 本综述探讨了脂质体的应用,制备和改善治疗干预的临床潜力.
科学领域:
- 制药科学 制药科学
- 生物技术是生物技术.
- 药物输送系统 药物输送系统
背景情况:
- 脂质体药物递送系统 (LDS) 是一种先进的药物递送方法.
- 脂质体是基于脂质的囊泡,能够运输各种治疗剂.
- 脂质体技术的进步使得对类风湿性关节炎等疾病的药物分配能够得到控制.
研究的目的:
- 审查脂质体药物递送系统,重点关注它们在类风湿性关节炎治疗中的应用.
- 为了整合关于脂质体制备,特征和施用途径的信息.
- 突出脂质体在类风湿性关节炎中新型治疗干预措施的潜力.
主要方法:
- 关于脂质体制备技术的文献综合审查.
- 分析涉及脂质体的临床试验,专利和销售配方.
- 对不同的囊泡类型和配方进行检查,以治疗类风湿性关节炎和其他疾病.
主要成果:
- 脂质体是生物相容,无毒,可生物降解和灵活的药物载体.
- 脂质体药物递送系统表现出超出局部管理的潜力,包括口服,眼部和亲肠道途径.
- 层状脂质体配方为药物输送提供了改进的特性.
结论:
- 脂质体药物递送系统已被确立为医疗应用的安全和适应性材料.
- 本综述为研究人员开发针对类风湿性关节炎的脂质体技术提供了宝贵的见解.
- 脂质体可能为管理类风湿性关节炎的创新治疗策略铺平道路.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
661
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
661
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
163
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
163
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
118
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
118

